Advertisement

Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer

      Highlights

      • With the expansion of available maintenance regimens in PSROC, treatment decisions have become increasingly complex.
      • Our value scorecards are a visual aid to discuss the harm-benefit balance of available maintenance therapies in PSROC.
      • Our data highlights the importance of germline and somatic testing to help differentiate treatment value.

      Abstract

      Objectives

      FDA-approved treatments for platinum-sensitive recurrent ovarian cancer (PSROC) include bevacizumab and PARP inhibitors (PARPi); clinical decisions regarding therapy must be made prior to initiating chemotherapy. Using the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) value frameworks, we assessed relative values of concurrent/maintenance biologic therapies in PSROC.

      Methods

      Value scores were calculated for key maintenance therapies based on randomized controlled trials: bevacizumab (OCEANS, GOG 213); olaparib (Study 19, SOLO2); niraparib (NOVA); rucaparib (ARIEL3). Personalized value scorecards were constructed for patients with germline/somatic-BRCA mutations, homologous recombination deficiency (HRD), and wild-type BRCA (wBRCA). ASCO value scores assess clinical benefit, toxicity, long-term survival, symptom palliation, treatment-free interval, and quality of life (QOL). ESMO value scores assess clinical benefit, toxicity, and QOL.

      Results

      ASCO scores were highest for maintenance PARPi in germline/somatic-BRCA mutation cohorts: olaparib (SOLO2) = 47, (Study 19) = 62; niraparib = 50; rucaparib = 54. HRD cohorts had slightly lower scores: niraparib = 46; rucaparib = 37. wBRCA cohorts had the lowest scores: niraparib = 26; rucaparib = 26; and olaparib (Study 19) = 32, as did patients receiving bevacizumab (OCEANS) = 35, (GOG 213) = 26. ESMO scores demonstrated high-value for maintenance PARPi in germline/somatic-BRCA mutation cohorts and low-value for bevacizumab and PARPi in wBRCA cohorts.

      Conclusions

      The value of maintenance PARPi therapy depends heavily on BRCA status, with the highest value scores in germline/somatic-BRCA mutation cohorts. Personalized value scorecards provide a visual aid to assess the harm-benefit balance of maintenance PARPi for PSROC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • U.S. Food and Drug Administration
        Center for Drug Evaluation and Research. Avastin (bevacizumab) BLA 125085/S-317, June 23, 2016.
        (Retrieved April 15, 2018, from)
        • U.S. Food and Drug Administration
        Center for Drug Evaluation and Research. Lynparza (olaparib) NDA 208558, February 22, 2017.
        (Retrieved April 15, 2018, from)
        • U.S. Food and Drug Administration
        Center for Drug Evaluation and Research. Zejula (niraparib) NDA 208447, October 31, 2017.
        (Retrieved April 15, 2018, from)
        • U.S. Food and Drug Administration
        Center for Drug Evaluation and Research. Rubraca (rucaparib) NDA 200115/S-003, April, 2018.
        (Retrieved April 15, 2018, from)
        • Schnipper L.E.
        • Davidson N.E.
        • et al.
        American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options.
        J. Clin. Oncol. 2015; 33: 2563-2577
        • Cherny N.I.
        • Sullivan R.
        • et al.
        A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society of Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
        Ann. Oncol. 2015; 26: 1547-1573
        • Schnipper L.E.
        • Davidson N.E.
        • et al.
        Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received.
        J. Clin. Oncol. 2016; 34: 2925-2934
        • Cherny N.I.
        • Dafni U.
        • et al.
        ESMO – magnitude of clinical benefit scale version 1.1.
        Ann. Oncol. 2017; 0: 1-27
        • Aghajanian C.
        • Blank S.V.
        • et al.
        OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
        J. Clin. Oncol. 2012; 30: 203945
        • Coleman R.L.
        • Brady M.F.
        • et al.
        Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-213): a multicenter, open-label, randomized, phase 3 trial.
        Lancet Oncol. 2017; 18: 779-791
        • Ledermann J.
        • Harter P.
        • et al.
        Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial.
        Lancet Oncol. 2014; 15: 852-861
        • Pujade-Lauraine E.
        • Ledermann J.A.
        • et al.
        Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA 1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1274-1284
        • Mirza M.R.
        • Monk B.J.
        • et al.
        Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
        N. Engl. J. Med. 2016; 375: 2154-2164
        • Coleman R.L.
        • Oza A.M.
        • et al.
        Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomized, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 390: 1949-1961
        • Ellis L.M.
        • Bernstein D.S.
        • et al.
        American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes.
        J. Clin. Oncol. 2014; 32: 1277-1280
        • Aghajanian C.
        • Goff B.
        • et al.
        Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
        Gynecol. Oncol. 2015; 139: 10-16
        • Ledermann J.A.
        • Harter P.A.
        • et al.
        Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomized, placebo-controlled, double-blind, phase 2 trial.
        Lancet Oncol. 2016; 17: 1579-1589
      1. SGO clinical practice statement: genetic testing for ovarian cancer.
        www.sgo.org
        Date: October 2014
        • Pal T.
        • Permuth-Wey J.
        • et al.
        BRCA 1 and BRCA 2 mutations account for a large proportion of ovarian carcinoma cases.
        Cancer. 2005; 104: 2807-2816
        • Schrader K.A.
        • Hurlburt J.
        • et al.
        Germline BRCA 1 and BRCA 2 mutations in ovarian cancer.
        Obstet. Gynecol. 2012; 120: 235-240
        • Walsh T.
        • Casadei S.
        • et al.
        Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
        PNAS. 2011; 108: 18032-18037
        • Cass I.
        • Baldwin R.L.
        • et al.
        Improved survival in women with BRCA-associated ovarian carcinoma.
        Cancer. 2003; 87: 2187-2195
        • Xu K.
        • Yang S.
        • Zhao Y.
        Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
        Oncotarget. 2017; 8: 285-302
        • De Picciotto N.
        • Cacheux W.
        • et al.
        Ovarian cancer: status of homologous recombination pathway as a predictor of drug response.
        Crit. Rev. Oncol. Hematol. 2016; 101: 50-59
        • Cohn D.E.
        • Barnett J.C.
        • et al.
        A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
        Gynecol. Oncol. 2015; 136: 293-299
        • Whysham W.Z.
        • Schaffer E.M.
        • et al.
        Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: a cost-effectiveness analysis of the AURELIA trial.
        Gynecol. Oncol. 2017; 145: 340-345
        • Berchuck A.
        • Alvarez Secord A.
        • et al.
        Maintenance Poly (ADP-ribose) polymerase inhibitor therapy for ovarian cancer: precision oncology or one size fits all?.
        J. Clin. Oncol. 2017; 35: 3999-4002
        • Liu A.Y.
        • Cohen J.G.
        • et al.
        A cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancer.
        Gynecol. Oncol. 2017; 147: 190-236
        • Zafar S.Y.
        • Abernethy A.P.
        Financial toxicity, part I: a new name for a growing problem.
        Oncology. 2013; 27: 80-149
        • Zafar S.Y.
        • Peppercorn J.M.
        • et al.
        The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience.
        Oncologist. 2013; 18: 381-390
        • Hanratty B.
        • Holland P.
        • et al.
        Financial stress and strain associated with terminal cancer—a review of the evidence.
        Palliat. Med. 2007; 21: 595-607
        • Norquist B.M.
        • Brady M.F.
        • et al.
        Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
        Clin. Cancer Res. 2018; 24: 777-783
        • Bentley T.G.K.
        • Cohen J.T.
        • et al.
        Measuring the value of new drugs: validity and reliability of 4 value assessment frameworks in the oncology setting.
        J. Manag. Care Spec. Pharm. 2017; 23: S34-S48